Nuwellis

Nuwellis FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Nuwellis (NUWE) as of Nov 9, 2026 is 62.21 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 86.44 % — a change of -28.03% (lower).

FCF Conversion

62.21 %

YoY

-28.03%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Nuwellis is 2025 62.21 % . FCF Conversion Rate (FCF/EBITDA) of Nuwellis was 2024 86.44 % . It decreases by -28.03% lower compared to the previous year.

The Nuwellis FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
86.65 USD
Jan 1, 2019
93.06 USD
Jan 1, 2020
106.53 USD
Jan 1, 2021
92.37 USD
Jan 1, 2022
105.14 USD
Jan 1, 2023
89.98 USD
Jan 1, 2024
86.44 USD
Jan 1, 2025
62.21 USD
The Nuwellis FCF Conversion history
YEARFCF ConversionYoY
62.21 %-28.03%
86.44 %-3.94%
89.98 %-14.41%
105.14 %+13.82%
92.37 %-13.29%
106.53 %+14.47%
93.06 %+7.40%
86.65 %-4.79%
91.01 %-12.41%
103.91 %+19.12%
87.23 %-2.94%
89.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nuwellis Stock analysis

What does Nuwellis do? Nuwellis, Inc. develops, manufactures, and commercializes medical devices for ultrafiltration therapy, primarily the Aquadex SmartFlow and Aquadex FlexFlow systems. The Aquadex System includes a console with electromechanical pumps and an LCD screen, a disposable blood circuit set, and a catheter. It targets patients with fluid overload unresponsive to diuretics, indicated for adult and pediatric use from 20 kilograms. Hospitals and healthcare providers purchase these systems to manage fluid overload in patients who have failed diuretic therapy. The company focuses on selling the Aquadex System as a comprehensive solution for ultrafiltration therapy. Nuwellis markets the Aquadex SmartFlow system specifically for temporary or extended use in patients with fluid overload unresponsive to medical management. The Aquadex FlexFlow system is part of the same product line, designed for similar therapeutic applications. The company's revenue comes from the sale of the Aquadex System components, including the console, disposable blood circuit sets, and catheters. Healthcare facilities are the primary buyers, using these devices to treat patients requiring ultrafiltration therapy. The Aquadex System is positioned as a medical device solution for fluid overload cases where diuretics have failed. It consists of a console, disposable blood circuit set, and catheter, all sold together as a system. Hospitals and clinics purchase the Aquadex System to provide treatment options for patients who cannot be managed with standard diuretic therapy. The company's revenue model relies on the sale of the complete system and its disposable components to healthcare providers. Nuwellis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nuwellis stock

FCF Conversion Rate (FCF/EBITDA) of Nuwellis is 62.21 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Nuwellis changed from 86.44 % to 62.21 %, representing a -28.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Nuwellis since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Nuwellis with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Nuwellis

All Key Metrics — Nuwellis